Tachykinins Mononuclear Phagocytes and HIV-1 Infection
Tachykinins Mononuclear Phagocytes and HIV-1 Infection
批准号:
8013561
负责人:
Steven Daniel Douglas
金额:
$38.68万
依托单位国家:
美国
项目类别:
财政年份:
1995
资助国家:
美国
项目状态:
已结题
起止时间:
1995-07-01 至 2013-01-31
关键词:
Acquired Immunodeficiency SyndromeAffectAgonistAmino Acid SequenceAstrocytesBasic Amino AcidsBrainBrain regionCCR5 geneCalciumCell Differentiation processCell LineCellsCellular biologyChemokine (C-C Motif) Receptor 5CouplingDefectDiseaseDown-RegulationEndocytosisFractalkineGene ExpressionGlycine decarboxylaseGoalsHIVHIV InfectionsHIV ReceptorsHIV SeropositivityHIV-1HumanIL8 geneImmuneImmune systemImpaired cognitionImpairmentIn VitroIndividualInfectionInflammatory Response PathwayInterleukin-6InvestigationLeadLengthLife StressLigandsLymphocyteMeasuresMediatingMediator of activation proteinMembraneMental DepressionMessenger RNAMicrogliaMononuclearNervous system structureNeurocognitiveNeuropeptidesPathogenesisPathway interactionsPeripheralPeripheral Blood Mononuclear CellPhagocytesPhenotypePlasmaPrevalenceProductionProgress ReportsProteinsPublic HealthRANTESRNARegulationResearch PersonnelRoleSamplingSignal TransductionSourceSubstance PSubstance P ReceptorSystemTACR1 geneTachykininTissuesUp-RegulationViral Load resultVirusWomanaprepitantarginyllysineautocrinebasechemokinechemokine receptorcingulate cortexcognitive functiondesignfeedingin vitro ModelmRNA Expressionmacrophagemenmonocyteneuropathologynovelnovel therapeutic interventionperipheral bloodprogramsprotein expressionreceptorreceptor functionrelease of sequestered calcium ion into cytoplasmresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The overarching goal of this investigation is to understand the mechanism(s) whereby the tachykinin neuropeptide, substance P (SP), and its preferred receptor, Neurokinin-lR (NK1R) modulate the immunopathogenesis of HIV as central mediators in the interaction between the immune and nervous systems. Our major hypothesis is that altered SP and NK1R, are mechanistically important in HIV pathogenesis and that this receptor and its ligand are altered in association with neurocognitive changes and life stress and depression in HIV-infected individuals. We showed that the non-peptide SP antagonist (CP-96,345) inhibits HIV replication in human mononuclear phagocytes through down-regulation of CCR5, the chemokine receptor, the principal co-receptor for HIV entry into macrophages and also by NK1R antagonist inhibition of endogenous SP production. The SP autocrine loop has an important role in regulating cytokine and inflammatory responses. HIV reciprocally enhances SP expression in human immune cells, eliciting a "feed-forward cycle". We discovered that cell differentiation in vitro from monocyte to macrophage phenotype (THP cells) results in the expression of both the NK1R-T (truncated) and NK1R-F (full-length), whereas the monocyte cell expresses only NK1R-T. The qualitative and quantitative expression of NK1R and its truncated (NK1R-T) and full length forms (NK1R-F) have functional consequences for calcium flux in macrophages. In the brain cingulate cortex, mRNA expression of both the NK1R-T and NK1R-F are reduced in HIV-infected subjects. We will use cells from both the immune and the CNS systems, including peripheral monocyte-macrophages and cells obtained from select human brain regions to examine these mechanisms. We will examine the cell biology of the interaction between NK1R (NK1R-F and NK1R-T) and HIV and chemokine receptors. Our aims are: (1) To investigate expression of NK-1RF in monocyte-derived macrophages and their associations with CCR5, CD4, Fractalkine, and IL-8. (2) We will investigate the physical and functional interactions between NK1R-T, NK1R-F receptors and CCR5. (3) We will explore the role of cytosolic Ca2+ increase in the cross-talk between NK1R-F, NK1R-T, and CCR5. (4) We hypothesize that altered levels of either or both NK1R-T or NK1R-F mRNA and protein, or receptor function, are associated with alterations with cognitive function in HIV-1/AIDS infected individuals, and these effects alter CCR5-NK1R interaction. Relevance to Public Health: These studies will further lead to understanding the pathogenesis of neurocognitive changes in HIV disease and lead to unique and novel therapeutic intervention.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NeuroAIDS Therapeutics-Targeting Immune Polarization of Macrophages in CNS
-
批准号:8929300
-
项目类别:
-
资助金额:$104.3万
-
财政年份:2014
-
负责人:Steven Daniel Douglas
-
依托单位:
NeuroAIDS Therapeutics-Targeting Immune Polarization of Macrophages in CNS
-
批准号:9288214
-
项目类别:
-
资助金额:$107.07万
-
财政年份:2014
-
负责人:Steven Daniel Douglas
-
依托单位:
NeuroAIDS Therapeutics-Targeting Immune Polarization of Macrophages in CNS
-
批准号:8790645
-
项目类别:
-
资助金额:$111.05万
-
财政年份:2014
-
负责人:Steven Daniel Douglas
-
依托单位:
Core E: Laboratory and biobehavioral marker core
-
批准号:10090667
-
项目类别:
-
资助金额:$23.82万
-
财政年份:2013
-
负责人:Steven Daniel Douglas
-
依托单位:
CD163 in HIV Immunopathogenesis
-
批准号:8601783
-
项目类别:
-
资助金额:$23.62万
-
财政年份:2013
-
负责人:Steven Daniel Douglas
-
依托单位:
NEUROKININ-1 RECEPTOR EXPRESSION IN THE BRAINS OF SIV-INFECTED RHESUS MACAQUES
-
批准号:8358142
-
项目类别:
-
资助金额:$5.78万
-
财政年份:2011
-
负责人:Steven Daniel Douglas
-
依托单位:
Core A
-
批准号:8102898
-
项目类别:
-
资助金额:$17.25万
-
财政年份:2010
-
负责人:Steven Daniel Douglas
-
依托单位:
NEUROKININ-1 RECEPTOR EXPRESSION IN THE BRAINS OF SIV-INFECTED RHESUS MACAQUES
-
批准号:8173056
-
项目类别:
-
资助金额:$6.18万
-
财政年份:2010
-
负责人:Steven Daniel Douglas
-
依托单位:
Project 5
-
批准号:8102897
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2010
-
负责人:Steven Daniel Douglas
-
依托单位:
Project 2
-
批准号:8102895
-
项目类别:
-
资助金额:$21.62万
-
财政年份:2010
-
负责人:Steven Daniel Douglas
-
依托单位:
Anti-HIV Neuroimmunomodulatory Therapy with Neurokinin-1 (NK1-R) Antagonists
-
批准号:8303327
-
项目类别:
-
资助金额:$112.34万
-
财政年份:2009
-
负责人:Steven Daniel Douglas
-
依托单位:
Anti-HIV Neuroimmunomodulatory Therapy with Neurokinin-1 (NK1-R) Antagonists
-
批准号:8526560
-
项目类别:
-
资助金额:$108.67万
-
财政年份:2009
-
负责人:Steven Daniel Douglas
-
依托单位:
Anti-HIV Neuroimmunomodulatory Therapy with Neurokinin-1 (NK1-R) Antagonists
-
批准号:7894593
-
项目类别:
-
资助金额:$113.83万
-
财政年份:2009
-
负责人:Steven Daniel Douglas
-
依托单位:
Anti-HIV Neuroimmunomodulatory Therapy with Neurokinin-1 (NK1-R) Antagonists
-
批准号:8102900
-
项目类别:
-
资助金额:$112.57万
-
财政年份:2009
-
负责人:Steven Daniel Douglas
-
依托单位:
Anti-HIV Neuroimmunomodulatory Therapy with Neurokinin-1 (NK1-R) Antagonists
-
批准号:7881910
-
项目类别:
-
资助金额:$116.63万
-
财政年份:2009
-
负责人:Steven Daniel Douglas
-
依托单位:
Project 2
-
批准号:7890832
-
项目类别:
-
资助金额:$23.18万
-
财政年份:2009
-
负责人:Steven Daniel Douglas
-
依托单位:
Core A
-
批准号:7659760
-
项目类别:
-
资助金额:$14.78万
-
财政年份:2008
-
负责人:Steven Daniel Douglas
-
依托单位:
Neurokinin-1R Antagonists-Cellular And Molecular Mechanisms
-
批准号:7658846
-
项目类别:
-
资助金额:$25.29万
-
财政年份:2008
-
负责人:Steven Daniel Douglas
-
依托单位:
Neurokinin-1R Antagonists-Cellular And Molecular Mechanisms
-
批准号:7516467
-
项目类别:
-
资助金额:$28.48万
-
财政年份:2007
-
负责人:Steven Daniel Douglas
-
依托单位:
Philadelphia IMPAACT Clinical Trials Unit
-
批准号:7096402
-
项目类别:
-
资助金额:$164.16万
-
财政年份:2007
-
负责人:Steven Daniel Douglas
-
依托单位:
海外基金